1. Future Directions in Myelofibrosis: Implications of Emerging Approaches

3. This program may include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Myeloproliferative Neoplasms

5. Diagnosis of Myelofibrosis

6. MYSEC-MF: A Molecular-Enriched Prognostic Model

7. Myelofibrosis

8. Factors Driving Therapy Choice in Myelofibrosis

9. Clinically Adjusted Treatment of Myelofibrosis

10. Treatment Algorithm for Anemia in MF

11. Treatment Is Dictated by Risk Category

12. MIPSS70 Risk Score: Variables Associated With Reduced OS

13. Indications of SCT in Myelofibrosis

14. JAK Inhibitors in Myelofibrosis

15. Impact on Disease Symptoms and QoL

16. COMFORT-II: Patient Disposition at 5 Years

17. JAK Inhibitors in Myelofibrosis

18. JAKARTA: Fedratinib in Myelofibrosis

19. Primary Endpoint: Spleen Response (ITT Population)

20. JAKARTA-2: Open-Label Study With Fedratinib

21. Fedratinib: Effective Second Line in MF — Results of JAKARTA 2

22. Review of Encephalopathy Cases

23. Pacritinib in MF: PERSIST Phase 3 Trials

24. SIMPLIFY-1: Primary Endpoint, Spleen; Secondary Endpoint, Reduction in Symptoms

25. SIMPLIFY-2: Primary Endpoint, SRR; Secondary Endpoint, TSS Response Rate

26. Non-JAK Inhibitors

27. Molecular and Histologic Remissions With Imetelstat

28. Pentraxin: Targeting Fibrosis

29. Sotatercept in MF

30. Long-Term Outcome of Patients With MPN-Associated Myelofibrosis Treated With Peg-Interferon α2a: FIM Study

31. Rationale for Drug Combination in MF

32. Preliminary Results of Ruxolitinib Combinations

33. JAK Inhibitor Plus Allografting

34. Preliminary Results of Ruxolitinib Combinations

35. Unmet Needs

36. How to Follow and Measure Efficacy

37. Immunotherapy

38. Conclusion

39. Abbreviations

40. Abbreviations (cont)

41. Abbreviations (cont)

42. Abbreviations (cont)